Illumina Unifies Genomics Software and AI Under BioInsight Platform

The platform consolidates Illumina’s diverse informatics portfolio—including BaseSpace, Emedgene, and the newly updated DRAGEN v4.6—into a single sign-on experience. This shift moves the company away from traditional annual subscriptions toward a usage-based credit model, intended to provide flexibility as scientific research requirements change. The core objective is to reduce the administrative burden of managing disjointed analytical tools, allowing laboratories to focus on variant effect prediction and disease biology.

Central to the release is the expansion of DRAGEN v4.6, which now offers increased deployment options across cloud and standard CPU environments. This update is already in use by the Global Parkinson's Genetics Program, which leverages the software to process large-scale cohort studies more consistently. Beyond processing, the BioInsight Data component harmonizes public and proprietary datasets into a reusable scientific catalog, while the BioInsight AI Lab provides models like SpliceAI2 for rare disease research. Illumina plans to demonstrate these capabilities at the American Society for Human Genetics annual meeting in Montreal.